Biom Completes safety and efficacy data of BIO017 in preclinical Angelman Syndrome mouse model. Biom Therapeutics’ Open label clinical study show preliminary efficacy data of BIO017 in epileptic patients

Biom Therapeutics files for orphan disease designation for lead candidate BIO017. Biom Therapeutics meeting with FDA for pre-IND meeting

Biom Therapeutics partnered with Canopy Growth. Biom Therapeutics partnered with Alchem for clinical drug manufacturing for pivotal study

Biom Therapeutics invited for Biopitch in Annual BioFlorida Annual Event. Biom Therapeutics in final three companies presenting in BioPitch in Annual BioFlorida Annual Event

Dr. Thomas Patton joins the Biom Therapeutics as Chief Medical Officer